Abstracts Archive - Page 103 of 2425 - ACR Meeting Abstracts

Abstract Number: 0932 • ACR Convergence 2024
IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
Grace Teng¹, Thomas Fung², Annamaria Mocciaro², Ceyda Llapashtica¹, Angie Hammond³, Jesse Gurgel⁴, zhiyu Huang¹, Maria Mouchess¹, Vanessa Gorney⁵, Wesley Minto¹, Sunish Mohanan¹, Adam Schrier¹, Wylie Palmer², Alexandra Borodovsky² and Gundula Min-oo¹, ¹Gilead Sciences, Foster City, CA, ²Nurix Therapeutics, San Francisco, CA, ³Gilead Sciences, Inc., Seattle, WA, ⁴Gilead Sciences, Seattle, CA, ⁵Alterome Therapeutics, San Diego, CA
Background/Purpose: Despite advances in treatment, chronic inflammatory diseases such as rheumatoid arthritis (RA) represent areas of high unmet medical need. IRAK4 is a proximal mediator…
Abstract Number: 0946 • ACR Convergence 2024
Tissue Resident Monocyte-lineage Cells (TR-MC) Exist as Two Different Subpopulations
Yidan Wang¹, Jessica Maciuch², Tyler Therron³, Carla Cuda², Deborah Winter⁴ and Harris Perlman², ¹Northwestern University, Hanover Park, IL, ²Northwestern University, Chicago, IL, ³Northwestern University, Chicago, ⁴Northwestern University, Skokie, IL
Background/Purpose: Monocytes are critical for the pathogenesis of rheumatoid arthritis (RA). However, depletion of peripheral monocytes (PM) is not sufficient to rescue disease in RA…
Abstract Number: 0752 • ACR Convergence 2024
Non-classical Organ Involvement in Giant Cell Arteritis
Javier Narvaez-García¹, paola Vidal¹, Pol Maymó², Judith Palacios³, Martí Aguilar Coll¹, Monserrat Roig Kim¹, Laia De Daniel¹ and Joan Miquel Nolla¹, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de Bellvitge., Barcelona, Spain, ³Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain
Background/Purpose: The increasing use of imaging techniques, particularly 18F-FDG PET-CT, has significantly expanded our understanding of giant cell arteritis (GCA). Our aim was to examine…
Abstract Number: 0051 • ACR Convergence 2024
Impact of Tight Junction Proteins on Inflammatory Processes and Microbial Imbalance in Rheumatoid Arthritis
Arkaitz Mucientes¹, jose Manuel Lisbona-Montañez², Patricia Ruiz-Limón³, Sara Manrique-Arija⁴, Aimara García-Studer⁴, Fernando Ortiz-Márquez⁴, Natalia Mena Vázquez⁵ and Antonio Fernández-Nebro⁶, ¹IBIMA Plataforma BIONAND, Malaga, Andalucia, Spain, ²University of Malaga, Malaga, Andalucia, Spain, ³IBIMA, Instituto de Biomedicina de Málaga, Cordoba, Spain, ⁴Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ⁵IBIMA, Málaga, Andalucia, Spain, ⁶Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain
Background/Purpose: The etiology of Rheumatoid Arthritis (RA) is not fully understood. Recent studies point to intestinal permeability as an important factor in the establishment and…
Abstract Number: 1087 • ACR Convergence 2024
Sex Differences in Clinical Features and Mortality in Gout: A Nationwide Retrospective Cohort Study
HYUNSUE DO¹, Kwanyoung Choe², Min Jung Kim³, Kichul Shin⁴ and Ki Won Moon⁵, ¹Kangwon national university hospital, Seoul, South Korea, ²Yeongjusi Health Center, Yeongjusi, Republic of Korea, ³Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea, ⁵Kangwon National University hospital, Chuncheon-si, Republic of Korea
Background/Purpose: Patients with gout have several coexisting conditions that impact mortality. Studies on clinical features and mortality of female patients with gout are limited, as…
Abstract Number: 1093 • ACR Convergence 2024
Risk of Dementia in Patients with Gout: Potential Impact of Survival Bias
Joshua Baker¹, Lindsay Helget², chung-Chou Chang³, Bryant England², Brian Coburn¹, Harlan Sayles², Punyasha Roul⁴ and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pittsburgh, Pittsburgh, PA, ⁴UNMC, Omaha, NE
Background/Purpose: Prior studies reported a lower risk of dementia among patients with gout suggesting that hyperuricemia might play a neuroprotective role. However, risk estimates for…
Abstract Number: 1076 • ACR Convergence 2024
Assessing the Reliability of ChatGPT on Recombinant Zoster Vaccination for Patients with Rheumatic and Musculoskeletal Diseases
Akhil Sood, Pegah Jahangiri, Amanda Moyer and Janice Lin, Stanford University, Palo Alto, CA
Background/Purpose: As artificial intelligence (AI) platforms continue to evolve, large language models (LLMs) such as ChatGPT by OpenAI are increasingly being utilized by patients and…
Abstract Number: 1074 • ACR Convergence 2024
Bending the Curve on Inbox Bloat: A Patient Portal Project to Mature-the-Message via Nurse Triage to Reduce Provider Inbox Time
Christie Bartels¹, Sancia Ferguson², Carmen Campbell¹, Lori Zemlicka³, Amanda Weber³, Andrew Holt¹ and Elizabeth R. Trowbridge⁴, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, Madison, Madison, WI, ³UW Health Rheumatology, Madison, WI, ⁴Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Clinical demands have grown, in part, from rising use of patient portals, while traditional clinic nurse triage has focused on phone-based care. We sought…
Abstract Number: 1053 • ACR Convergence 2024
Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases
Kai Sun¹, Lisa Carnago², Isaac Smith³, Brian Andonian¹, Stephen Balevic¹, Ankoor Shah¹, Catherine Sims⁴, Kathryn Pollak⁵, Amy Corneli⁵, Hayde Bosworth⁵ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke Health, Hillsborough, NC, ³Duke University Hospital, Durham, NC, ⁴Duke University, Knightdale, NC, ⁵Duke University, Durham, ⁶Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is as high as 75% among patients with rheumatic diseases, leading to increased morbidity, mortality, and cost. Existing adherence interventions tend to…
Abstract Number: 1071 • ACR Convergence 2024
Rapid Access Microscopy and Real Time Case Discussion via a Secure Messaging App Improves Diagnostic Accuracy and Management of Acute Hot Swollen Joints
Anouchka Lewis¹, John Stack², Oisin Corish², Callum Swift², Tomás Breslin², Frank Lyons², Eavan Muldoon², Cian McDermott², Sharon Cowley², Helina Alemayehu², Oliver Boughton², Khaled Taha² and Geraldine McCarthy², ¹The Mater Misericordiae University Hospital, Dublin, Ireland, ²Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with acute swollen joints are often presumed to have septic arthritis, leading to treatment with intravenous antibiotics and arthroscopic washout. Previously at our…
Abstract Number: 1008 • ACR Convergence 2024
Immune Responses to Infection and Autoimmune Diseases in the UK Biobank
Choa Yun¹, May A. Beydoun², Lenore Launer² and Minkyo Song³, ¹National Institute on Aging, Rockville, MD, ²National Institute on Aging, Baltimore, MD, ³National Institutes on Aging, Baltimore, MD
Background/Purpose: Infections have been implicated as potential triggers for autoimmune responses, but studies primarily focused on the history of infection linked with autoimmune diseases. Large-scale…
Abstract Number: 1102 • ACR Convergence 2024
Risk of Mortality and Major Cardiovascular-Kidney Outcomes in Patients with Tophaceous versus Non-Tophaceous Gout
Gregory Challener¹, kevin sheng-kai ma¹, Natalie McCormick¹, Chio Yokose², Alex Tinianow¹ and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: While it is well established that patients with gout have increased mortality risk compared to the general population [1, 2, 3], it is less…
Abstract Number: 1051 • ACR Convergence 2024
Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis
Daniel Labson¹, Qian Cai², Concetta Crivera³ and Federico Zazzetti⁴, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Raritan, NJ, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Global Market Access RWE, Titusville, NJ, ³Janssen Global Services, LLC, a Johnson & Johnson Company, Immunology Market Access, Horsham, PA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare autoimmune conditions primarily characterized by muscle weakness and inflammation. Real-world evidence on economic outcomes of patients with…
Abstract Number: 1067 • ACR Convergence 2024
Initiation of Urate-Lowering Therapy in Patients Hospitalized with Gout Flare at a Single Center: Opportunity for Quality Improvement
Ali Nasir¹ and Nasir Khan², ¹Trinity Health Grand Rapids/Michigan State University, Grand Rapids, MI, ²Trinity Health Grand Rapids, Grand Rapids, MI
Background/Purpose: Hospitalizations for gout flare have been increasing, doubling between 1993 to 2011 from 4.4 to 8.8 admissions per 100000 adults. Despite this increase, urate-lowering therapy (ULT)…
Abstract Number: 1073 • ACR Convergence 2024
Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting
Catherine Vo, Chialin Nguyen, Scott Hagan, Sheida Aalami and Elizabeth Wahl, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: The 2020 ACR Guideline for the Management of Gout conditionally recommends testing for the HLA-B*5801 risk allele prior to starting allopurinol for patients of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].